(A) This panel highlights potential directions for future investigations into the relationship between allergies and brain immunology in the context of gliomagenesis. Emphasis is placed on studying glioma risk, prognosis and treatment response. (B) Biomarker-driven analysis, utilizing current and upcoming clinically relevant markers for allergies, can aid in defining patient phenotypes and endotypes. Coupled with the sub-classification of gliomas based on integrated diagnosis (refer to Table 1), this approach holds the potential to address various unanswered questions in the field (as described in Box 2). (C) Next-generation AllergoOncology studies could incorporate the use of relevant biomarkers for allergy and glioma classification, particularly in large patient cohorts. It is essential to establish high-resolution epidemiological cohorts with comprehensive individual characteristics (including demographics, medical records with comorbidity and treatment information), as well as biospecimens (such as blood, serum, feces, PBMC, and hair) collected over the lifetime or at etiologically relevant time points. This will enable integrated multi-omics analysis. (D) Innovative in-vitro and in-vivo models are necessary to further elucidate the causative molecular mechanisms underlying AllergoOncology. Stratification approaches can play a crucial role in fulfilling these research needs. (E) The ultimate objective is to sustain the development of innovative clinical trials aimed at advancing new therapeutics in the field of AllergoOncology. Created with « BioRender.com».